DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cytarabine (Cytarabine) - Death - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Death (92)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cytarabine where reactions include death. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 92   Next >>

Possible Cytarabine side effects in

Reported by a physician from United States on 2012-08-15

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: 60 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Decadron
    Dosage: 10 mg/m2, cyclic
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Oncaspar
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-08-15

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: 60 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2, cyclic
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-08-15

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia

Oncaspar
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Decadron
    Dosage: 10 mg/m2, cyclic
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: 60 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-08-15

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Decadron
    Dosage: 10 mg/m2, cyclic
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Oncaspar
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: 60 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-08-15

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2, cyclic
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: 60 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-08-15

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Methotrexate
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Decadron
    Dosage: 10 mg/m2, cyclic
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: 60 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Oncaspar
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-08-15

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Doxorubicin Hydrochloride
    Dosage: 60 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2, cyclic
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Dosage: unk, cyclic
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia



Possible Cytarabine side effects in female

Reported by a physician from United States on 2012-07-26

Patient: female

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine

Temozolomide
    Indication: Brain Neoplasm

Etoposide
    Administration route: Oral

Velcade
    Indication: Brain Neoplasm



Possible Cytarabine side effects in 50 year old female

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-06

Patient: 50 year old female

Reactions: Haemoptysis, Refractoriness To Platelet Transfusion, Petechiae, Pancytopenia, Febrile Neutropenia, Pyrexia, Alveolitis Allergic, Death, Panniculitis, Colitis, Thrombocytopenia, Laryngospasm, Klebsiella Sepsis

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Immune Globulin NOS
    Indication: Pancytopenia

Mitoxantrone
    Dosage: 10 mg/m2 on d1-5; 2nd induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Idarubicin HCL
    Dosage: 12 mg/m2 on d1-3; induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Cytarabine
    Dosage: 100 mg/m2 on d1-7; induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Etoposide
    Dosage: 100 mg/m2 on d1-5; 2nd induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Other drugs received by patient: Vercyte



Possible Cytarabine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Elspar
    Indication: Acute Lymphocytic Leukaemia

Prednisone
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Idarubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Indication: Acute Lymphocytic Leukaemia



Possible Cytarabine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Prednisone TAB
    Indication: Acute Lymphocytic Leukaemia

Elspar
    Indication: Acute Leukaemia

Idarubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Dexamethasone



Possible Cytarabine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Idarubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Prednisone TAB
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Indication: Acute Lymphocytic Leukaemia

Elspar
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Indication: Acute Lymphocytic Leukaemia



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-06-26

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Dexamethasone
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Indication: Burkitt's Lymphoma

Methotrexate
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Monoclonal Antibodies
    Dosage: standard dose
    Indication: Acute Lymphocytic Leukaemia

Monoclonal Antibodies
    Dosage: standard dose
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Rituximab
    Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: ALL Other Therapeutic Drugs



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-06-26

Patient:

Reactions: Death, Neoplasm Malignant, Burkitt's Lymphoma Recurrent, Myelodysplastic Syndrome, Burkitt's Leukaemia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Indication: Burkitt's Lymphoma

Methotrexate
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Monoclonal Antibodies
    Dosage: standard dose
    Indication: Acute Lymphocytic Leukaemia

Monoclonal Antibodies
    Dosage: standard dose
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Indication: Burkitt's Lymphoma

Dexamethasone
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Unknown Medication



Possible Cytarabine side effects in

Reported by a physician from Germany on 2012-06-21

Patient:

Reactions: Alanine Aminotransferase Increased, Arrhythmia, Death, Neurotoxicity, Mucosal Inflammation, Lung Disorder, Aspartate Aminotransferase Increased, Cardiotoxicity, Cardiac Failure Congestive, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Granulocyte Colony Stimulating Factor
    Dosage: induction 2; day 21-28
    Indication: Acute Myeloid Leukaemia

Daunorubicin HCL
    Dosage: induction 2; day 21-28
    Indication: Acute Lymphocytic Leukaemia

Idarubicin HCL
    Dosage: induction 1; day 1

Etoposide
    Dosage: induction 1; day 1
    Indication: Acute Lymphocytic Leukaemia

Cladribine
    Dosage: between days 42-56; consolidation phase
    Indication: Acute Lymphocytic Leukaemia

Cladribine
    Dosage: between days 42-56; consolidation phase
    Indication: Acute Myeloid Leukaemia

Cytarabine
    Dosage: day 42-56 (0.5g/m2), consolidation phase
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: induction 2; high dose; days 21-28

Idarubicin HCL
    Dosage: induction 1; day 1

Etoposide
    Dosage: induction 1; day 1
    Indication: Acute Myeloid Leukaemia

Idarubicin HCL
    Dosage: day 42-56; consolidation phase
    Indication: Acute Myeloid Leukaemia

Granulocyte Colony Stimulating Factor
    Dosage: induction 2; day 21-28
    Indication: Acute Lymphocytic Leukaemia

Daunorubicin HCL
    Dosage: induction 2; day 21-28
    Indication: Acute Myeloid Leukaemia

Cytarabine
    Dosage: day 42-56 (0.5g/m2), consolidation phase
    Indication: Acute Myeloid Leukaemia

Cytarabine
    Dosage: induction 2; high dose; days 21-28

Idarubicin HCL
    Dosage: day 42-56; consolidation phase
    Indication: Acute Lymphocytic Leukaemia

Fludarabine Phosphate
    Dosage: induction 2; day 21-28
    Indication: Acute Myeloid Leukaemia

Cytarabine
    Dosage: induction 1; day 1

Cytarabine
    Dosage: induction 1; day 1

Mitoxantrone
    Dosage: induction 2; day 21-28
    Indication: Acute Lymphocytic Leukaemia

Mitoxantrone
    Dosage: induction 2; day 21-28
    Indication: Acute Myeloid Leukaemia

Fludarabine Phosphate
    Dosage: induction 2; day 21-28
    Indication: Acute Lymphocytic Leukaemia



Possible Cytarabine side effects in

Reported by a physician from Germany on 2012-06-18

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Cladribine
    Dosage: between days 42-56; consolidation phase
    Indication: Acute Myeloid Leukaemia

Cytarabine
    Dosage: day 42-56 (0.5g/m2), consolidation phase

Cytarabine
    Dosage: induction 1; day 1
    Indication: Acute Myeloid Leukaemia

Idarubicin HCL
    Dosage: day 42-56; consolidation phase
    Indication: Acute Myeloid Leukaemia

Cytarabine
    Dosage: induction 2; high dose; days 21-28

Etoposide
    Dosage: induction 1; day 1
    Indication: Acute Myeloid Leukaemia

Idarubicin HCL
    Dosage: induction 1; day 1

Mitoxantrone
    Dosage: induction 2; day 21-28
    Indication: Acute Myeloid Leukaemia



Possible Cytarabine side effects in 41 year old male

Reported by a health professional (non-physician/pharmacist) from Spain on 2012-06-15

Patient: 41 year old male

Reactions: Death, non-Hodgkin's Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Clofarabine
    Dosage: unk
    Indication: non-Hodgkin's Lymphoma

Fludara
    Dosage: unk
    Indication: Bone Marrow Conditioning Regimen

Cytarabine
    Dosage: unk
    Indication: non-Hodgkin's Lymphoma

Other drugs received by patient: Thiotepa; Busulfan



Possible Cytarabine side effects in 26 year old male

Reported by a health professional (non-physician/pharmacist) from Spain on 2012-06-15

Patient: 26 year old male

Reactions: Death, non-Hodgkin's Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: unk
    Indication: non-Hodgkin's Lymphoma

Fludara
    Dosage: unk
    Indication: Bone Marrow Conditioning Regimen

Clofarabine
    Dosage: unk
    Indication: non-Hodgkin's Lymphoma

Other drugs received by patient: Busulfan; Thiotepa



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-06-12

Patient:

Reactions: Death, Burkitt's Lymphoma Recurrent, Neoplasm Malignant, Myelodysplastic Syndrome, Burkitt's Leukaemia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Doxorubicin HCL
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Burkitt's Lymphoma

Methotrexate
    Indication: Burkitt's Lymphoma

Monoclonal Antibodies
    Dosage: standard dose
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Monoclonal Antibodies
    Dosage: standard dose
    Indication: Acute Lymphocytic Leukaemia

Rituximab
    Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
    Indication: Burkitt's Lymphoma

Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Unknown Medication



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-06-12

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Indication: Chromosome Analysis Abnormal

Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Dasatinib
    Dosage: first 14 days of each of 8 cycles of alternating hypercvad
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Chronic Myeloid Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Indication: Chronic Myeloid Leukaemia

Doxorubicin Hydrochloride
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Dasatinib
    Dosage: first 14 days of each of 8 cycles of alternating hypercvad
    Administration route: Oral
    Indication: Chronic Myeloid Leukaemia

Methotrexate
    Indication: Chronic Myeloid Leukaemia

Methotrexate
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Indication: Chronic Myeloid Leukaemia

Cyclophosphamide
    Indication: Chronic Myeloid Leukaemia

Dexamethasone
    Indication: Chronic Myeloid Leukaemia



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-06-12

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Burkitt's Lymphoma

Monoclonal Antibodies
    Dosage: standard dose
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: Burkitt's Lymphoma

Monoclonal Antibodies
    Dosage: standard dose
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: ALL Other Therapeutic Drugs



Possible Cytarabine side effects in female

Reported by a physician from United States on 2012-06-06

Patient: female

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Indication: Brain Neoplasm

Temozolomide
    Indication: Brain Neoplasm

Etoposide
    Administration route: Oral
    Indication: Brain Neoplasm

Velcade
    Indication: Brain Neoplasm



Possible Cytarabine side effects in

Reported by a individual with unspecified qualification from Denmark on 2012-06-01

Patient:

Reactions: Neurotoxicity, Death, Sepsis, Haematotoxicity

Adverse event resulted in: death

Drug(s) suspected as cause:
Temozolomide
    Indication: Central Nervous System Lymphoma

Dexamethasone
    Indication: Central Nervous System Lymphoma

Ifosfamide
    Indication: Central Nervous System Lymphoma

Vincristine
    Indication: Central Nervous System Lymphoma

Mabthera
    Indication: Central Nervous System Lymphoma

Cyclophosphamide
    Indication: Central Nervous System Lymphoma

Cytarabine

Methotrexate
    Indication: Central Nervous System Lymphoma

Cytarabine
    Indication: Central Nervous System Lymphoma

Vindesine
    Indication: Central Nervous System Lymphoma



Possible Cytarabine side effects in female

Reported by a physician from United Kingdom on 2012-05-22

Patient: female

Reactions: Death

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-03

Everolimus
    Dosage: unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-03



Possible Cytarabine side effects in 61 year old male

Reported by a physician from Greece on 2012-05-18

Patient: 61 year old male

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Methotrexate Sodium
    Indication: Leukaemia

Cytarabine
    Indication: Leukaemia

Doxorubicin HCL
    Indication: Leukaemia



Possible Cytarabine side effects in 30 year old female

Reported by a physician from France on 2012-05-07

Patient: 30 year old female

Reactions: Bronchopulmonary Aspergillosis, Death, Acute Respiratory Distress Syndrome

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Evoltra
    Indication: Acute Myeloid Leukaemia

Cytarabine
    Indication: Acute Myeloid Leukaemia

Cyclophosphamide
    Dosage: unk
    Indication: Bone Marrow Conditioning Regimen
    Start date: 2011-11-26
    End date: 2011-11-30

Thymoglobulin
    Dosage: unk
    Indication: Bone Marrow Conditioning Regimen
    Start date: 2011-11-26
    End date: 2011-11-30

Cyclophosphamide
    Indication: Acute Myeloid Leukaemia

Evoltra
    Dosage: unk
    Indication: Bone Marrow Conditioning Regimen
    Start date: 2011-11-26
    End date: 2011-11-30

Cytarabine
    Dosage: unk
    Indication: Bone Marrow Conditioning Regimen
    Start date: 2011-11-26
    End date: 2011-11-30

Thymoglobulin
    Indication: Acute Myeloid Leukaemia



Possible Cytarabine side effects in 61 year old male

Reported by a physician from Greece on 2012-05-02

Patient: 61 year old male

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Methotrexate Sodium
    Indication: Leukaemia

Doxorubicin HCL
    Indication: Leukaemia

Cytarabine
    Indication: Leukaemia



Possible Cytarabine side effects in 45 year old male

Reported by a health professional (non-physician/pharmacist) from Spain on 2012-04-30

Patient: 45 year old male

Reactions: Neurological Decompensation, Graft Versus Host Disease, Central Nervous System Lesion, Hemiparesis, Iiird Nerve Disorder, Viith Nerve Paralysis, Myoclonus, Death, Cranial Nerve Disorder, Progressive Multifocal Leukoencephalopathy, Asthenia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Mycophenolate Mofetil
    Dosage: 2 g, per day
    Start date: 2009-12-01

Cytarabine
    Dosage: 200 mg/m2, per day for 7 days
    Indication: Acute Myeloid Leukaemia
    Start date: 2008-12-01

Cytarabine
    Dosage: two more cycles

Idarubicin HCL
    Dosage: two cycles

Fludarabine Phosphate
    Dosage: 160 mg/m2, for conditioning
    Indication: Bone Marrow Conditioning Regimen

Busulfan
    Dosage: 12.8 mg/kg, unk
    Indication: Bone Marrow Conditioning Regimen

Fludarabine Phosphate
    Dosage: two cycles
    Indication: Acute Myeloid Leukaemia

Cyclosporine
    Dosage: 5 mg/kg, per day
    Administration route: Oral
    Indication: Graft Versus Host Disease

Idarubicin HCL
    Dosage: 12 mg/m2, per day for 3 days
    Indication: Acute Myeloid Leukaemia

Tacrolimus
    Dosage: 0.1 mg/kg, per day
    Indication: Graft Versus Host Disease

Prednisone
    Dosage: 2 mg/kg, per day
    Administration route: Oral
    Indication: Graft Versus Host Disease

Sirolimus
    Indication: Graft Versus Host Disease

Other drugs received by patient: Gemtuzumab Ozogamicin; Granulocyte Colony Stimulating Factor



Possible Cytarabine side effects in 45 year old male

Reported by a health professional (non-physician/pharmacist) from Spain on 2012-04-30

Patient: 45 year old male

Reactions: Neurological Decompensation, Graft Versus Host Disease, Central Nervous System Lesion, Hemiparesis, Viith Nerve Paralysis, Iiird Nerve Disorder, Death, Myoclonus, Cranial Nerve Disorder, Progressive Multifocal Leukoencephalopathy, Asthenia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclosporine
    Dosage: 5 mg/kg, per day
    Administration route: Oral
    Indication: Graft Versus Host Disease

Tacrolimus
    Dosage: 0.1 mg/kg, per day
    Indication: Graft Versus Host Disease

Prednisone
    Dosage: 2 mg/kg, per day
    Administration route: Oral
    Indication: Graft Versus Host Disease

Sirolimus
    Indication: Graft Versus Host Disease

Cytarabine
    Dosage: two more cycles

Fludarabine Phosphate
    Dosage: two cycles
    Indication: Acute Myeloid Leukaemia

Mycophenolate Mofetil
    Dosage: 2 g, per day
    Start date: 2009-12-01

Idarubicin HCL
    Dosage: 12 mg/m2, per day for 3 days
    Indication: Acute Myeloid Leukaemia

Idarubicin HCL
    Dosage: two cycles

Cytarabine
    Dosage: 200 mg/m2, per day for 7 days
    Indication: Acute Myeloid Leukaemia
    Start date: 2008-12-01

Fludarabine Phosphate
    Dosage: 160 mg/m2, for conditioning
    Indication: Bone Marrow Conditioning Regimen

Busulfan
    Dosage: 12.8 mg/kg, unk
    Indication: Bone Marrow Conditioning Regimen

Other drugs received by patient: Granulocyte Colony Stimulating Factor; Gemtuzumab Ozogamicin



Possible Cytarabine side effects in

Reported by a physician from United States on 2012-04-27

Patient:

Reactions: Death, Nervous System Disorder, Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Doxorubicin HCL
    Indication: Lymphoma

Vincristine
    Indication: Lymphoma

Cytarabine
    Indication: Lymphoma

Rituximab
    Indication: Lymphoma

Prednisone
    Indication: Lymphoma

Methotrexate
    Indication: Lymphoma

Cyclophosphamide
    Indication: Lymphoma

Dexamethasone
    Indication: Lymphoma



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017